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ABSTRACT (207w) 
Background 
Patients with severe asthma respond less well to corticosteroids than those with 
non-severe asthma. Increased p38 mitogen-activated protein kinase (MAPK) 
activation in alveolar macrophages (AMs) from severe asthma patients has been 
associated with a reduced inhibition of cytokine release by dexamethasone.  
Question of the study 
We determined whether p38 MAPK inhibitors would modulate corticosteroid 
suppression of cytokine release from AMs and peripheral blood mononuclear 
cells (PBMC). 
Methods 
PBMCs were isolated from venous blood and AMs by bronchoalveolar lavage in 
severe and non-severe asthma patients.   PBMCs and AMs were exposed to 
lipopolysaccharide (LPS) with and without the p38 MAPK inhibitor, SD282,  or 
dexamethasone. We determined the concentration-dependent effects of another 
p38 MAPK inhibitor, GW-A, on dexamethasone-induced inhibition of IL-8 release 
from PBMCs. Cytokines were assayed using an ELISA-based method. 
Results 
SD282 (10-7M), with dexamethasone (10-6M), caused a greater inhibition of 
release of IL-1β, IL-6, MIP-1α and IL-10 than with dexamethasone alone in AMs 
from severe and non-severe asthma. At 10-9 and 10-10M GW-A, that had no direct 
effects, increased the inhibitory activity of dexamethasone (10-8 and 10-6M) on 
LPS-induced IL-8 release in PBMCs from severe asthma. Similar results were 
observed with IL-6 release.     
Answer  to the question. 
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Corticosteroid insensitivity in severe asthma patients may be improved by 
inhibitors of p38 MAPK.  
 
Key words 
Alveolar macrophages, corticosteroid-resistant asthma, cytokines, p38 mitogen-
activated protein kinase, severe asthma. 
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Introduction 
Most asthma patients are well-controlled on inhaled corticosteroid therapy 
(ICS), but a small proportion experience continuing symptoms. These patients 
labelled as having severe asthma consume a more significant proportion of 
medical resources in terms of drugs, admissions to hospital or use of emergency 
services, and time off work or school [1]. Definitions and the clinical features of 
recently-described cohorts attest to the persistent loss of control of asthma 
despite the optimal use of asthma medication. Such patients demonstrate a poor 
response to the therapeutic effects of corticosteroids. Peripheral blood 
mononuclear cells (PBMCs) and alveolar macrophages (AMs) from patients with 
severe asthma are less sensitive to inhibition by dexamethasone in terms of the 
stimulated release of pro-inflammatory cytokines, when compared with cells from 
well-controlled non-severe asthma patients[2;3].  
The mechanisms underlying this poor suppressive response to 
corticosteroids in severe asthma are unclear, but many  have been proposed from 
in vitro studies in cells[4]. We observed that AMs from patients with severe 
asthma demonstrated a greater degree of activation of p38 mitogen-activated 
protein kinase (MAPK) [2]. p38 MAPK is a family of serine-threonine kinase that 
act on a variety of substrates including transcription factors, such as  NF-κB and 
AP-1 and has been implicated in inflammation, cell proliferation and cell death 
relevant to asthma pathophysiology[5]. We hypothesised that activation of p38 
MAPK could be linked to the reduced inhibition of cytokine release by 
corticosteroids since part of the action of corticosteroids may relate to inhibition of 
MAPK activation. In addition, p38 MAPK activation has been previously shown to 
induce corticosteroid insensitivity in peripheral blood mononuclear cells through 
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phosphorylation of the glucocorticoid receptor[6], indicating one potential 
mechanism of corticosteroid insensitivity. 
Selective inhibitors of p38 MAPK, mainly the α isoform, have been 
developed. In seeking to implicate a role for p38 MAPK activation in corticosteroid 
sensitivity, we examined whether inhibitors of p38 MAPK could improve the ability 
of dexamethasone in suppressing cytokine release in AMs and PBMCs from 
patients with severe asthma.  
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METHODS 
Study participants 
Asthma patients with either bronchodilator responses to albuterol of  ≥12% of 
baseline FEV1 or with a methacholine PC20 of <16mg/ml (Table 1) were recruited 
from the Royal Brompton Severe Asthma Clinic. Current and ex-smokers of >5 
pack-years were excluded. Severe asthmatics were defined according to the ATS 
criteria[7]. Non-severe asthmatic patients used 0-2,000 µg of inhaled 
beclomethasone-equivalent per day with control of their asthma. The protocols 
were approved by the local Ethics Committee. All volunteers gave written 
informed consent.  
 
Isolation of Alveolar Macrophages 
Fibreoptic bronchoscopy was performed with intravenous midazolam and 
alfentanyl.  Broncho-alveolar lavage (BAL) was performed in the right middle lobe 
with 0.9% NaCl solution. Macrophages (5 x 105/well) were purified by adhesion to 
plastic wells for 4 hours and then exposed for 18 hours to LPS (10 μg/ml) in the 
presence or absence of dexamethasone (10-6 M)  or of a selective p38 MAPK 
inhibitor, SD282 (10-7M; Scios Inc, Freemont, CA) [8;9] or both.  
 
Isolation of PBMCs 
Venous blood (80 ml) was diluted 1:1 with Hanks buffered saline solution (HBSS) 
and layered on Ficoll-Hypaque-Plus. Following centrifugation, PBMCs were re-
suspended in culture media, plated (7.5x105 cells/well) and stimulated with 
LPS(10μg/ml) with or without dexamethasone (10-6 M) or SD282 (10-7M) or both. 
Supernatants at 18 hours were analysed for MIP-1α, IL-1β, IL-6 and IL-10. 
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LPS-stimulated PBMCs were also used  to examine the effect of GW-A(10-
12-10-6M), a p38 MAPK inhibitor from GlaxoSmithKline, or dexamethasone (10-12-
10-6M) or of the combination of GW-A  and dexamethasone on IL-8 release. 
 
p38 MAPK phosphorylation 
To determine p38 MAPK activity, PBMCs were stimulated with LPS overnight in 
the presence or absence of dexamethasone (10-8 M) and/or GW-A (10-9 M).    
The contents of each well were stored in Beadlyte cell lysis buffer B (Beadlyte®, 
Upstate Technology, NY) at -70ºC for later assay for phosphorylated and total 
p38 MAPK using microsphere beads coated with antibodies to P-p38 and total 
p38 using the Beadlyte® protocol.  
 
Measurement of cytokine release  
The cytokines MIP-1α, IL-1β, IL-6 and IL-10 were assayed simultaneously using 
microsphere beads (Beadlyte®) coated with capture antibodies. Biotinylated 
reporter antibodies were used to bind the microsphere bead-cytokine 
complexes. Finally, a fluorophore, streptavidin-phycoerythrin was added to bind 
the biotinylated reporter and the fluorescent signal measured in a laser 
spectrophotometer (Luminex Corporation, Austin, TX). Microsphere beads for 
each cytokine emitted a unique ratio of two other fluorophores. IL-8 was 
measured using ELISA.  
 
Data analysis  
Results were expressed as mean ± SEM.  Cytokine release induced by LPS with 
or without dexamethasone or p38 MAPK inhibitor was calculated by subtraction of 
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baseline release. The release of each cytokine following dexamethasone + LPS 
was calculated as a percentage of cytokine release following LPS stimulation 
alone. Corticosteroid sensitivity between severe asthma and non-severe asthma 
patients was compared using the Mann-Whitney U test.  The effect of SD282 on 
the suppressive effect of dexamethasone was analysed by Wilcoxon paired t-test.  
Concentration-dependent responses were examined using one-way-ANOVA 
(Kruskal-Wallis test) followed by a Dunn’s Multiple Comparison test.  p<0.05 was 
taken as significant. 
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RESULTS 
Corticosteroid insensitivity in AMs and PBMCs    
Baseline and LPS-stimulated release of IL-1β, IL-6, MIP-1α and IL-10 from 
both AMs and PBMCs did not significantly differ between patients with severe 
asthma and patients with non-severe asthma. There was less inhibition of 
cytokine release from AMs in the severe asthma group compared with that in the 
non-severe group for IL-1β, IL-6 and MIP-1α with the percentage of cytokine 
release after LPS and dexamethasone to that after LPS alone being 71± 8 vs 26 
±7, p<0.01; 52 ± 9 vs 20 ± 5, p<0.05; 70 ± 9 vs 28 ± 7, p<0.01), respectively. 
There was no significant difference regarding IL-10 (12 ± 4 vs 30 ±10) (Fig 1A).    
       For PBMCs, there was a non-significant trend for less suppression by 
dexamethasone in patients with severe asthma compared with non-severe 
asthma:  IL-1β (46 ± 19 vs 27 ± 8); IL-6 (35 ± 8 vs 22 ±6); MIP-1α (48 ±14 vs 45 ± 
19); IL-10 (68 ± 10 vs 42 ±9) (Fig 1B).  
 
Effect of SD282 on dexamethasone inhibition of cytokine release 
       In AMs from non-severe asthma, the suppressive effect of dexamethasone 
was relatively greater than that of SD282, and there was more inhibition of IL-6 
and MIP-1α with the combination, with a trend towards greater suppression for 
IL-1β (Fig 2A). In AMs from severe asthma, SD282 alone caused only a small 
degree of suppression of LPS-induced IL-1β, IL-6, MIP-1α and IL−10 release, 
being similar in magnitude to that seen with dexamethasone alone (Fig 2B). 
Combined SD282 and dexamethasone caused a greater inhibition of cytokine 
release compared with dexamethasone alone for the four cytokines.  
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      In PBMCs, the inhibitory effect of SD282 was greater than that observed in 
AMs.  Although there were significant differences between the effect of 
dexamethasone and that of dexamethasone and SD282 for the release of all four  
cytokines, with less effect on the release of MIP-1α, from PBMCs of non-severe 
asthma patients, there was no evidence of additivity in the presence of both 
dexamethasone and SD282 (Fig 3A). Similar observations were made in PBMCs 
from -severe asthma patients (Fig 3B).   
 
Effect of dexamethasone and GW-A on p38 activation and IL-8 release from 
PBMCs  
To determine whether GW-A (10-9M) demonstrates inhibitory effects on p38 
MAPK activity, the ratio of phosphorylated p38 to total p38 was measured at 24 
hours. GW-A (10-9M) alone or in combination with dexamethasone (10-8M) 
attenuated p38 activity induced by LPS stimulation (Figure 4). 
In order to determine whether there was additivity or synergy between 
dexamethasone and a p38 MAPK inhibitor, we measured the inhibitory effect of 
dexamethasone and GW-A alone on LPS-induced IL-8 release from PBMCs from 
severe asthmatics. A maximal inhibition of 51.2  ± 4.01 % release was achieved at 
10-6M  dexamethasone with an IC50 of 3.9x10-7M, while GW-A caused maximal 
suppression of 51.6 ± 7.1% at 10-6M with an IC50  of 3.7 x 10-7M.  
The effect of dexamethasone at 10-6M (Fig 5A) in suppressing IL-8 release 
was improved in the presence of GW-A (10-10-10-6M) (p<0.0001, one-way-
ANOVA) with a maximal suppression of 89.6 ± 2.6 %  with GW-A at 10-6 and 10-
7M, compared with 51.9 ± 4.0%  suppression with dexamethasone alone 
(p<0.001).  At  GW-A 10-9M  and 10-10M,  which alone had an inhibitory effect of 
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less than 3 %,  IL-8 suppression by dexamethasone (10-6M) was increased to 76.8 
± 3.5 % (p<0.05) and 70.1 ± 2.0 % (p<0.01), respectively (Fig 5B).   
At dexamethasone (10-8M), the inhibitory effect was also improved in the 
presence of GW-A (p< 0.001, one-way-ANOVA), with maximal suppression with 
GW-A (10-6M) being 73.4 ± 4.5 % as compared with 31.3 ± 3.8 % with 
dexamethasone alone. Similar effects were observed with dexamethasone at a 
concentration of 10-9 M, in combination with GW-A (Fig 5A). We obtained similar 
results when examining the release of IL-6 (Fig 6). 
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DISCUSSION 
            We have  previously shown impaired corticosteroid sensitivity in AMs and 
PBMCs from patients with severe asthma and increased activation of p38 MAPK 
in AMs of severe asthmatics [2;3]. We now demonstrate that a low concentration  
of a p38 MAPK inhibitor, SD282, that had little effect on IL-1β, IL-6 and MIP-1α 
release improved the inhibitory activity of dexamethasone in AMs from severe 
asthma patients. This effect was not observed in PBMCs from patients with 
severe asthma because the concentration of SD282 chosen had a major 
suppressive effect on cytokine release. To investigate more closely any 
interaction between p38 MAPK inhibition and corticosteroids, we studied a wider 
range of concentrations of another p38 MAPK inhibitor, GW-A, and showed an 
enhancement of the suppressive effects of dexamethasone in PBMCs from 
patients with severe asthma at concentrations of GW-A that had no effect on IL-8 
release. For example, the maximal suppression of IL-8 release obtained with the 
highest concentration of dexamethasone (10-6M), was also achieved with a 100-
fold reduction in dexamethasone concentration (10-8M) with addition of GW-A 
(10-9M). The enhancement in the inhibitory effects of dexamethasone appears to 
be synergistic because the suppression by dexamethasone (10-8M) by GW-A (10-
9M) alone were 28% and 3%, respectively, whereas the suppression observed 
when added in combination was increased to 59 %.  
            It is of interest that there was also additivity in the effects of SD282 and 
dexamethasone in AMs from patients with non-severe asthma in suppressing the 
release of IL-1β, IL-6 and MIP-1α, albeit to a lesser extent, even though the 
degree of inhibition by dexamethasone alone was substantial.  However, this was 
not seen with IL-10 release in AMs from non-severe asthma patients, but was 
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present in AMs from severe asthma patients.  Therefore, overcoming 
corticosteroid insensitivity by using p38 MAPK inhibitors can be demonstrated in 
severe asthmatics. Our data is supported by a recent study that reported that a 
p38 MAPK inhibitor in combination with dexamethasone caused a greater 
suppression of gene expression induced by LPS in monocyte-derived 
macrophages or AMs [10]. 
          The p38 MAPK inhibitor, SD282, is an indole-5-carboxamide selective 
p38α MAPK inhibitor demonstrating a 14.3-fold greater potency for p38α 
compared with p38β  [8;9]. No detectable effect on other closely-related kinases 
such as p38δ, p38γ, jun-N-terminal kinase and p38 activating kinases at 
concentrations up to 50 mM in human PBMCs has been observed [8], and 
therefore these effects are likely to result from the selective inhibition of the p38α 
MAPK isoform.  GW-A is another p38 MAPK inhibitor that is currently in clinical 
development [11]. We have shown that concentrations of GW-A (10-9 and 10-10M) 
that had no effect on cytokine release, still demonstrated significant inhibition of 
p38 MAPK activity in peripheral blood monocytes exposed to LPS. This suggests 
that p38 MAPK activation is associated with corticosteroid insensitivity. 
Phosphorylation of p38 MAPK was measured as an indicator  of the efficacy of 
GW-A, rather than one of its downstream targets based on studies which have 
demonstrated that p38 inhibitors can prevent phosphorylation of p38α in vitro 
[12;13]. Additional  studies have demonstrated that p38α can auto-phosphorylate 
[14] and  trans-phosphorylate(19). Finally, SB203508, another p38 MAPK 
inhibitor related to GW-A, inhibits the enzymatic activity of both activated and 
unactivated forms of p38α [15].   
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                   A role for p38 MAPK activation in severe asthma has been 
suggested by the observation that macrophages from such patients demonstrate 
increased p38 MAPK activation when exposed to LPS [2] . Previous studies have 
indicated a role for p38 MAPK activation in murine asthma models. Thus, in a 
chronic allergen model, suppression of p38α MAPK by an inhibitor or by 
antisense oligonucleotides attenuated ovalbumin-induced bronchial 
hyperreactivity, eosinophilia, goblet cell hyperplasia, airway smooth muscle 
hypertrophy and bronchial hyperresponsiveness, through a reduction of Th2-
cytokines associated with allergic inflammation [16;17]. Another potential effect  
of p38 inhibition is the reversal of corticosteroid insensitivity that is present in 
severe asthma [3]. We have previously demonstrated that IL-2- and IL-4-
mediated corticosteroid insensitivity of peripheral blood mononuclear cells can be 
reversed by inhibition of p38 MAPK activity [6].  This insensitivity was reflected by 
a reduction in corticosteroid ligand binding affinity due to phosphorylation of the 
GR, that could be reversed by a p38 MAPK inhibitor [6], or by an indirect effect 
on the ligand binding domain of GR [18].  On the other hand, p38 MAPK 
activation may also lead to phosphorylation and phosphoacetylation of histones 
in the promoter regions of NF-κB dependent genes such as those activated by 
LPS resulting in enhanced recruitment of the transcription factor NF-κB 
[19;20]This is consistent with previous observations that  histone deacetylase 
(HDAC) activity is reduced in PBMCs and alveolar macrophages of asthmatic 
patients [3;21].  
 
p38 MAPK activation may be involved in the stabilisation and increased 
translation of pro-inflammatory cytokine mRNA, dependent on the conserved AU-
 14
rich elements in the 3’-UTR region [22]. Of the proinflammatory cytokine mRNAs 
that can be stabilised by p38 MAPK activation in monocyte and macrophage cell 
lines, IL-1β, IL-6, IL-8, and MIP-1α [23-25] are the same cytokines that were less 
inhibited by dexamethasone in alveolar macrophages from severe asthma 
patients, and where the extent of inhibition by dexamethasone was correlated 
with the degree of p38 MAPK activation [3]  These potential downstream effects 
of p38 MAPK do not lead to enhanced release of cytokines from the alveolar 
macrophages but to a reduction in the effectiveness of corticosteroids. Although 
this study has focused on p38 MAPK activity in this study, activation of other 
members of the MAPK family such as c-jun N-terminal kinase (JNK) and 
extracellular signal-regulated kinase ERK [26;27] have also been implicated in 
corticosteroid insensitivity. Whether there are interactions between the parallel 
downstream pathways to influence corticosteroid sensitivity deserves further 
investigation. In previous studies, we have also shown the reduced induction of 
MAKP phosphatase-1 (MKP-1) by dexamethasone in AMs from patients with 
severe asthma [2]. This suggests another potential mechanism for increased 
activation of p38 MAPK activity.  
        The effect of dexamethasone in inhibiting IL-10 release induced by LPS 
from AMs and PBMCs may seem contradictory when induction of IL-10  release 
by corticosteroids has been shown in ex vivo studies of alveolar macrophages or 
blood monocytes from patients who have been treated with either inhaled 
corticosteroids [28]  or systemic methylprednisolone [29] . However, direct 
incubation of monocytes or AMs stimulated by LPS with deaxmethasone led to 
an inhibition of IL-10 as we [2;3] and others [29]  have shown. p38 MAPK 
inhibition also reduced IL-10 release from PBMCs or AMs, as confirmed recently 
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in monocytes [30]. .  We found that teh combi9nation of dexamethasone and 
GW-A caused an increase in inhibition of IL-10 release, particularly in PBMCs 
and AMs from patients with severe asthma.  
 
Patients with severe asthma need effective new medications that will improve 
their asthma control. Our study points to a novel approach to the treatment of 
severe asthma. A p38 MAPK inhibitor may be used as an anti-inflammatory agent 
and has been shown to be  effective in this way in asthma models [16;17]. We 
have used this inhibitor to demonstrate its capacity to reverse corticosteroid 
insensitivity. Immunosuppressive drugs such as cyclosporin A and methotrexate 
have been administered in patients with steroid-dependent asthma to lower 
maintenance oral corticosteroid dosage, while allowing the control of asthma to 
remain unchanged [31;32], but these drugs have not proven to be useful. A p38 
MAPK inhibitor could be effective in reversing corticosteroid insensitivity at lower 
doses than those needed to inhibit inflammation with a lesser risk of side-effects, 
but will need to be used concomitantly with corticosteroids.  
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 FIGURE LEGENDS 
Figure 1. Concentrations of cytokines in cell culture supernatants of alveolar 
macrophage (A & B) and peripheral blood mononuclear cells (A & C) from 
patients with non-severe and severe asthma, at baseline (A) and  stimulated with 
LPS (10 μg/ml) in the presence and absence of dexamethasone (10-6M). There 
were no significant differences in baseline  and stimulated levels of IL-1β, IL-6, 
MIP-1α and IL-10 between patients with severe and non-severe asthma.  There 
was a significant decrease in release of  cytokines in the presence of 
dexamethasone for both cell types and both patient groups.  
 
Figure 2. Inhibition of LPS-induced cytokine (IL-1β, IL-6, MIP-1α, IL-10) release 
from alveolar macrophages of a group of 6 non-severe (Panel A) and 6  severe 
asthmatics (Panel B) by  p38 MAPK inhibitor (SD282; 10-7M), dexamethasone 
(10-6M), or both. *  p<0.05.  
 
Figure 3. Inhibition of LPS-induced cytokine (IL-1β, IL-6, MIP-1α) release from 
PBMCs of a group of 6 non-severe (Panel A) and 6  severe asthmatics (Panel B) 
by  p38 MAPK inhibitor (SD282; 10-7M), dexamethasone (10-6M), or both. * 
p<0.05, ** p<0.01.  
 
Figure 4.   Inhibition of LPS-induced p38 phosphorylation in peripheral blood 
mononuclear cells from severe asthmatic patients (n=3) by the p38 inhibitor, GW-
A (553; 10-9 M) in the presence or absence of dexamethasone (Dex; 10-8 M). ** p < 
0.01,  * p < 0.05.   
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Figure 5. Inhibition of LPS-induced IL-8 release from peripheral blood 
mononuclear cells by the p38 inhibitor, GW-A (n=8), in the presence of different 
concentrations of dexamethasone (Panel A), and by dexamethasone in the 
presence of different concentrations of GW-A (Panel B).  *** p < 0.001, ** p < 
0.01,  * p < 0.05 compared to dexamethasone, at the given concentration,  alone.  
 
Figure 6.  Inhibition of LPS-induced IL-6 release from peripheral blood 
mononuclear cells by the p38 inhibitor, GW-A (n=5), in the presence of different 
concentrations of dexamethasone (Panel A), and by dexamethasone in the 
presence of different concentrations of GW-A (Panel B).  *** p < 0.001, ** p < 
0.01, compared to dexamethasone, at the given concentration,  alone.  
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Table 1.   
A. Characteristics of non-severe and severe asthma subjects in the SD282 study  
 
BAL Non-severe asthma Severe asthma 
Gender (F:M) 3:3 5:1 
Age (years) 32.8 ± 3.88 47±2.67 
FEV1 (% predicted) 89.8 ± 3.28 52.8± 7.73*** 
Bronchodilator response 
(%)1
9.1 ± 2.24 23.3 ±3.97 
Log PC20 (mg/ml) 0.52 ± 0.15 -0.60± 0.18 
Prednisolone (mg/day) 0 12.5 ± 4.33** 
BDP equivalent (μg/day) 33.3 ± 33.3 2800 ± 744*** 
BAL Cells    
Total count (x106) 5.85  ± 0.81 5.05 ± 0.49 
Macrophage (%) 94.55 ± 1.37 92.9 ± 1.63 
Neutrophils (%) 1.8 ± 0.46 3.32 ± 1.57* 
Eosinophils (%) 1.13 ± 0.51 1.25 ± 0.82 
Lymphocytes (%) 2.54 ± 0.43 2.53 ± 1.12 
PBMC Non-severe asthma Severe asthma 
Gender (F:M) 2:4 5:1 
Age (years) 36.7 ± 3.61 43.2 ± 5.71 
FEV1 (% predicted) 88.2 ± 3.32 55.2± 8.19*** 
Bronchodilator response 
(%)1
8.7 ± 2.0 21.3 ± 9.4 
Log PC20 (mg/ml) 0.0 ± 0.28 0.1 ± 0.09 
Prednisolone (mg/day) 0 8.3 ± 4.01* 
BDP equivalent (μg/day) 333.3 ± 151 3200 ± 722*** 
 
B. Characteristics of severe asthma subjects in the GW-A study.  
 
PBMC Severe asthma 
Gender (F:M) 6:2 
Age (years) 43.2 ± 5.71 
FEV1 (% predicted) 68.8 ± 8.19 
Bronchodilator 
response (%)1
20.1 ± 8.4 
Log PC20 (mg/ml) -1.67 ± 0.21 
Prednisolone 
(mg/day) 
16.25 ± 8 
BDP equivalent 
(μg/day) 
1725 ± 146 
*p<0.05; **p≤0.01; ***p≤0.001 compared to non-severe asthma 
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Abbreviations: BAL: bronchoalveolar lavage; BDP: beclomethasone 
dipropionate; F=female; M=male; FEV1=forced expiratory volume in one 
second; FVC= forced vital capacity; PC20= provocative concentration of 
methacholine causing a 20% fall in FEV1; PBMC= Peripheral blood 
mononuclear cells. Values represent mean ± SEM.  1Measured as per cent 
increase over baseline FEV1 after 400 μg albuterol aerosol.  
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